Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.20.1.263PMID 11773178
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2000

  2000cited by this paper
• Preoperative staging of non-small-cell lung cancer with positron-emission tomography.

  2000cited by this paper
• The current role of mediastinoscopy in the evaluation of thoracic disease.

  1999cited by this paper
• Cost-Efficacy of Endoscopic Ultrasonography with Fine-Needle Aspiration vs. Mediastinotomy in Patients with Lung Cancer and Suspected Mediastinal Adenopathy

  1999cited by this paper
• Utility valuations for outcome states of colorectal cancer

  1999cited by this paper
• Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT.

  1999cited by this paper
• Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease.

  1999cited by this paper
• Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.

  1998cited by this paper
• The role of mediastinoscopy in the diagnosis of mediastinal lymphadenopathy.

  1998cited by this paper
• Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).

  1997cited by this paper
• Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging.

  1997cited by this paper
• Cost of combined modality interventions for stage III non-small-cell lung cancer.

  1997cited by this paper
• Revisions in the International System for Staging Lung Cancer.

  1997cited by this paper
• Cost of Care for Cancer in a Health Maintenance Organization

  1997cited by this paper
• Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

  1996cited by this paper
• Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes.

  1995cited by this paper
• The cost of managing lung cancer in Canada.

  1995cited by this paper
• Investigation for mediastinal disease in patients with apparently operable lung cancer. Canadian Lung Oncology Group.

  1995cited by this paper
• Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group.

  1995cited by this paper
• Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.

  1995cited by this paper
• Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer.

  1994cited by this paper
• A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

  1994cited by this paper
• Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease).

  1994cited by this paper
• The role of CT and MRI in staging of the mediastinum.

  1994cited by this paper
• Practicing medicine without a license.

  1994cited by this paper
• Comparative costs of lung cancer management.

  1994cited by this paper
• Stacked inspiratory spirometry reduces pulmonary shunt in patients after coronary artery bypass.

  1994cited by this paper
• A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

  1994cited by this paper
• Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients.

  1994cited by this paper
• N2 lung cancer: outcome in patients with false-negative computed tomographic scans of the chest.

  1993cited by this paper
• Markov Models in Medical Decision Making

  1993cited by this paper
• Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.

  1993cited by this paper
• Management of metastatic non-small-cell lung cancer and a consideration of cost.

  1993cited by this paper
• Outpatient mediastinoscopy.

  1993cited by this paper
• Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.

  1993cited by this paper
• Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.

  1991cited by this paper
• Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.

  1991cited by this paper
• Routine computed tomographic scans, selective mediastinoscopy, and other factors in evaluation of lung cancer.

  1991cited by this paper
• Aggressive surgical intervention in N2 non-small cell cancer of the lung.

  1991cited by this paper
• A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.

  1990cited by this paper
• Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis.

  1990cited by this paper
• Cost-effectiveness of CT scanning compared with mediastinoscopy in the preoperative staging of lung cancer.

  1989cited by this paper
• Clinical Economics: A Guide to the Economic Analysis of Clinical Practices

  1989cited by this paper
• The value of mediastinoscopy in preoperative staging of bronchogenic carcinoma.

  1989cited by this paper
• Mediastinal Staging in Non-small-cell Lung Cancer

  1989cited by this paper
• Cost-effectiveness of CT scanning compared with mediastinoscopy in the preoperative staging of lung cancer.

  1989cited by this paper
• Bronchogenic carcinoma metastatic to normal-sized lymph nodes: frequency and significance.

  1988cited by this paper
• Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer.

  1988cited by this paper
• Cost effectiveness of chest CT in T1N0M0 lung cancer.

  1988cited by this paper
• Prognosis and survival in resected lung carcinoma based on the new international staging system.

  1988cited by this paper
• Incidence of mediastinal node involvement in clinical T1 bronchogenic carcinomas.

  1987cited by this paper
• Decision analysis.

  1987cited by this paper
• A new international staging system for lung cancer.

  1987cited by this paper
• A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma.

  1987cited by this paper
• Evaluation of the mediastinum by invasive techniques.

  1987cited by this paper
• The contribution of anterior mediastinotomy in the diagnosis and evaluation of diseases of the mediastinum and lung.

  1987cited by this paper
• The new International Staging System for Lung Cancer.

  1986cited by this paper
• Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung.

  1986cited by this paper
• Measurement of health state utilities for economic appraisal.

  1986cited by this paper
• Predilection of lung cancer for the upper lobes: an epidemiologic inquiry.

  1984cited by this paper
• Nonmedical costs to patients and their families associated with outpatient chemotherapy

  1984cited by this paper
• Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases.

  1983cited by this paper
• The Markov Process in Medical Prognosis

  1983cited by this paper
• Modern thirty-day operative mortality for surgical resections in lung cancer.

  1983cited by this paper
• A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making.

  1982cited by this paper
• A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

  1982cited by this paper
• The threshold approach to clinical decision making.

  1980cited by this paper
• Foundations of cost-effectiveness analysis for health and medical practices.

  1977cited by this paper
• Resection for bronchial carcinoma in the elderly

  1973cited by this paper
• Parasternal mediastinotomy and mediastinoscopy. Adjuncts in the diagnosis of chest disease.

  1973cited by this paper
• Mediastinoscopy.

  1970cited by this paper
• Diagnostic anterior mediastinotomy.

  1966cited by this paper
• © 1999 Cancer Research Campaign Article no. bjoc.1998.0426 Cost-effectiveness of paclitaxel plus cisplatin in

  year unknowncited by this paper

• [Discussion. Meeting on the diagnosis and treatment of lung cancer].

  2014cites this paper
• Elicitation of health state utilities in neuroendocrine tumours

  2012cites this paper
• First data on direct costs of lung cancer management in Morocco.

  2012cites this paper
• 肺癌术前常规纵隔淋巴结外科分期的临床价值

  2010cites this paper
• A Review and Meta-Analysis of Utility Values for Lung Cancer

  2010cites this paper
• The recent advance of positron emission tomography (PET) also led to many physicians not using mediastinoscopy because PET has higher sensitivity and specificity than CT for the assessment of mediastinal lymph nodes

  2010cites this paper
• Much Cheaper, Almost as Good: Decrementally Cost-Effective Medical Innovation

  2009cites this paper
• Costs of the detection of metastases and follow-up examinations in cutaneous melanoma

  2009cites this paper
• The cost of lung cancer in Alberta.

  2007cites this paper
• Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.

  2007cites this paper
• Financial Aspects of Lung Cancer

  2006cites this paper
• Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?

  2005cites this paper
• Estimating Patient Time Costs Associated With Colorectal Cancer Care

  2005cites this paper
• Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.

  2005cites this paper
• Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter?

  2004cites this paper
• Nuclear YB‐1 expression as a negative prognostic marker in nonsmall cell lung cancer

  2004cites this paper
• Recent Advances in the Treatment of Stage IIIA Lung Cancer

  2003cites this paper
• Institutional review - Thoracic general Invasive staging of superior mediastinum in non-small cell lung cancer patients with specific indications q

  2003cites this paper
• Invasive staging of superior mediastinum in non-small cell lung cancer patients with specific indications.

  2003cites this paper
• Restaging after induction therapy for non-small cell lung cancer.

  2002cites this paper